Lineage Cell Therapeutics (LCTX) Gross Margin (2011 - 2026)
Lineage Cell Therapeutics (LCTX) posted quarterly Gross Margin of 100.0% for Q1 2026, up 240.0% year-over-year from 29.41% in Q1 2025, and up 1.01% quarter-over-quarter from 99.0% in Q4 2025.
Lineage Cell Therapeutics (LCTX) Gross Margin (2011 - 2026) Analysis & Trends
Lineage Cell Therapeutics' Gross Margin history runs 16 years deep, the most recent figure standing at 100.0% for Q1 2026.
- In Q1 2026, Gross Margin rose 240.0% year-over-year to 100.0%; the TTM figure through Mar 2026 stood at 99.26% (up 210.0% YoY), while the FY2025 annual figure was 99.0%, up 251.0% from the prior year.
- Gross Margin for Q1 2026 stood at 100.0%, up from 99.0% in the prior quarter.
- The five-year high for Gross Margin was 100.0% in Q1 2026, with the low at 86.44% in Q3 2023.
- The 5-year median for Gross Margin is 96.06% (2023), against an average of 95.46%.
- The sharpest annual moves came in 2022 and 2023: Gross Margin surged 9275 bps in 2022, then tumbled 693 bps in 2023.
- Lineage Cell Therapeutics' Gross Margin stood at 94.67% in 2022, then declined by 7 bps to 87.74% in 2023, then climbed by 8 bps to 94.63% in 2024, then grew by 5 bps to 99.0% in 2025, then advanced by 1 bps to 100.0% in 2026.
- Business Quant data shows LCTX's Gross Margin at 100.0% in Q1 2026, 99.0% in Q4 2025, and 99.86% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 90.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 89.76% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 60,631,834.75% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 76.90% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 84.20% |
| 10 | Lineage Cell Therapeutics | 270.61 Mn | 212.77 Mn | 1.07 Mn | 100.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 100.00% |
| Mar 31, 2026 | 100.00% |
| Dec 31, 2025 | 99.00% |
| Sep 30, 2025 | 99.86% |
| Jun 30, 2025 | 98.59% |
| Mar 31, 2025 | 97.60% |
| Dec 31, 2024 | 94.63% |
| Sep 30, 2024 | 98.99% |
| Jun 30, 2024 | 96.88% |
| Mar 31, 2024 | 93.21% |
| Dec 31, 2023 | 87.74% |
| Sep 30, 2023 | 86.44% |
| Jun 30, 2023 | 96.06% |
| Mar 31, 2023 | 95.01% |
| Dec 31, 2022 | 94.67% |
| Sep 30, 2022 | 92.16% |
| Jun 30, 2022 | 95.28% |
| Mar 31, 2022 | 96.64% |
| Dec 31, 2021 | 1.93% |
| Sep 30, 2021 | 56.61% |